25.232.16 100th Legislative Session 35
2025 South Dakota Legislature
Senate Bill 35
ENROLLED
AN ACT
ENTITLED An Act to modify substances listed on the controlled substances schedule
and to declare an emergency.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA:
Section 1. That § 34-20B-13 be AMENDED:
34-20B-13. Any of the following opium derivatives and opiates, their salts,
isomers, esters, ethers, and salts of isomers, esters, and ethers, is included in Schedule
I, unless specifically excepted, whenever the existence of the salts, isomers, esters,
ethers, and salts of isomers, esters, and ethers is possible within the specific chemical
designation:
(1) Acetylcodone;
(2) Benzylmorphine;
(3) Codeine methylbromide;
(4) Codeine-N-Oxide;
(5) Desomorphine;
(6) Drotebanol;
(7) Heroin;
(8) Hydromorphinol;
(9) Methyldesorphine;
(10) Methylhydromorphine;
(11) Morphine methylbromide;
(12) Morphine methylsulfonate;
(13) Morphine-N-Oxide;
(14) Myrophine;
(15) Nicocodeine;
(16) Nicomorphine;
(17) Normorphine; 25.232.16 2 35
SB35 ENROLLED
(18) Thebacon;
(19) 3-Methylfentanyl;
(20) Fentanyl analogs. Any substituted derivatives of fentanyl unless specifically
excepted, listed in another schedule, or contained within a pharmaceutical product
approved by the United States Food and Drug Administration, that is structurally
related to fentanyl by modification in any one or more of the following ways:
(a) By replacement of the phenyl portion of the phenethyl group by any
monocycle whether or not further substituted in or on the monocycle;
(b) By substitution in or on or replacement of the phenethyl group with alkyl,
alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
(c) By substitution in or on the piperadine ring with alkyl, alkenyl, alkoxyl,
ester, ether, hydroxyl, halo, haloalkyl, amino, phenyl, substituted phenyl,
or nitro groups;
(d) By replacement of the aniline ring with any aromatic monocycle whether or
not further substituted in or on the aromatic monocycle; or
(e) By the replacement of the N-propionyl group by another acyl group.
Some trade and other names: N -(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl
fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl
fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl,
acryloylfentanyl); N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-
fluorofentanyl or 2 -fluorofentanyl); N -(1-phenethylpiperidin-4-yl)-N-
phenyltetrahydrofuran-2-carboxamide (tetrahydrofuranyl fentanyl); 2 -methoxy-N-(1-
phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl fentanyl); N -(1-
phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl), N -
phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide (valeryl fentanyl); N -(1-
phenethylpiperidin-4-yl)-N-phenylbutyramide (butyrl fen tanyl); N-[1-(2-hydroxy-2-
thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide (Beta-Hydroxythiofentanyl); N-
(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para -fluorobutyryl
fentanyl); N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para-
methoxybutyryl fentanyl); N -(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide (para-chloroisobutyryl fentanyl); N-(1-phenethylpiperidin-4-yl)-N-
phenylisobutyramide (isobutyryl fentanyl); N -(1-phenethylpiperidin-4-yl)-N-
phenylcyclopentanecarboxamide (cyclopentyl fentanyl); N -(2-fluorophenyl)-2-methoxy-
N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); N -(4-fluorophenyl)-N-(1- 25.232.16 3 35
SB35 ENROLLED
phenethylpiperidin-4-yl)isobutyramide (para-fluoroisobutyryl fentanyl); (E) -N-(1-
phenethylpiperidin-4-yl)-N-phenylbut-2-enamide (Crotonyl fentanyl);
(21) 1-Methyl-4-phenyl-4-propionoxypiperidine;
(22) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;
(23) 3,4-dichloro-N[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700);
(24) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45);
(25) 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide (AH -7921);
(26) 2-(2,4-dichlorophenyl)-N-2-(dimethylamino)cyclohexyl)-N-methylacetamide (U -
48800);
(27) Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (U -
49900);
(28) N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide
(Methylenedioxy-U-47700);
(29) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropylbenzamide (Isopropyl-
U-47700);
(30) 1-(1,2-Diphenylethyl)piperidine (Diphenidine);
(31) N-Ethyl-1,2-diphenylethylamine (Ephenidine);
(32) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-
2-one (Brorphine);
(33) 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol)
(Zipeprol); and
(34) 2-Methyl AP-237 (1Methyl-4(3Phenylprop-2-en-1-yl)Piperizin-1-yl)Butan-1-one).
Section 2. That § 34-20B-14 be AMENDED:
34-20B-14. Any material, compound, mixture, or preparation that contains any
quantity of the following hallucinogenic substances, their salts, isomers, and salts of
isomers, is included in Schedule I, unless specifically excepted, whenever the existence of
such salts, isomers, and salts of isomers is possible within the specific chemical
designation:
(1) Bufotenine;
(2) Diethyltryptamine (DET);
(3) Dimethyltryptamine (DMT);
(4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
(5) 5-methoxy-3, 4-methylenedioxy amphetamine;
(6) 4-bromo-2, 5-dimethoxyamphetamine; 25.232.16 4 35
SB35 ENROLLED
(7) 4-methoxyamphetamine;
(8) 4-methoxymethamphetamine;
(9) 4-methyl-2, 5-dimethoxyamphetamine;
(10) Hashish and hash oil;
(11) Ibogaine;
(12) Lysergic acid diethylamide;
(13) Mescaline;
(14) N-ethyl-3-piperidyl benzilate;
(15) N-methyl-3-piperidyl benzilate;
(16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP);
(17) Peyote, except that when used as a sacramental in services of the Native American
church in a natural state which is unaltered except for drying or curing and cutting
or slicing, it is hereby excepted;
(18) Psilocybin;
(19) Psilocyn;
(20) Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in
§ 38-35-1; in a drug product approved by the United States Food and Drug
Administration; or marijuana in its natural and unaltered state; including any
compound, except nabilone or compounds listed under a different schedule,
structurally derived from 6,6Ν dimethyl-benzo[c]chromene by substitution at the
3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups,
whether or not the compound is further modified in any of the following ways:
(a) By partial to complete saturation of the C-ring; or
(b) By substitution at the 1-position with a hydroxyl or methoxy group; or
(c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl
group; or
(d) By modification of the possible 3-alkyl group with a 1,1Ν dimethyl moiety, a
1,1Ν cyclic moiety, an internal methylene group, an internal acetylene
group, or a terminal halide, cyano, azido, or dimethylcarboxamido group.
Some trade and other names: JWH -051; JWH-057; JWH-133; JWH-359; HHC; AM-
087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243;
HU-336;
(21) 3, 4, 5-trimethoxy amphetamine;
(22) 3, 4-methylenedioxy amphetamine;
(23) 3-methoxyamphetamine; 25.232.16 5 35
SB35 ENROLLED
(24) 2, 5-dimethoxyamphetamine;
(25) 2-methoxyamphetamine;
(26) 2-methoxymethamphetamine;
(27) 3-methoxymethamphetamine;
(28) Phencyclidine;
(29) 3, 4-methylenedioxymethamphetamine (MDMA);
(30) 3, 4-methylenedioxy-N-ethylamphetamine;
(31) N-hydroxy-3, 4-methylenedioxyamphetamine;
(32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);
(33) 2,5 Dimethoxy-4-ethylamphetamine;
(34) N,N-Dimethylamphetamine;
(35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine;
(36) Aminorex;
(37) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-
oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
(38) Cathinone and other variations, defined as any compound, material, mixture,
preparation or other product unless listed in another schedule or an approved FDA
drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-
position with either phenyl, naphthyl, or thiophene ring systems, whether or not
the compound is further modified in any of the following ways:
(a) By substitution in the ring system to any extent with alkyl, alkylenedioxy,
alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further
substituted in the ring system by one or more other univalent substitutents;
(b) By substitution at the 3-position with an acyclic alkyl substituent; or
(c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a
cyclic structure.
Some trade or other names: methcathinone, 4 -methyl-N-methylcathinone
(mephedrone); 3,4 -methylenedioxy-N-methylcathinone (methylone); 3,4 -
methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4 -
flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-
PMMA); Ethcathinone (N -Ethylcathinone); 3,4-methylenedioxyethcathinone
(ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N -
dimethylcathinone (metamfepramone); Alpha -pyrrolidinopropiophenone (alpha-
PPP); 4 -methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4 - 25.232.16 6 35
SB35 ENROLLED
methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha -
pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4Ν-Methyl-alpha-
pyrrolidinobutiophenone (MPBP); Methyl -α-pyrrolindinopropiophenone (MPPP);
Methyl-α-pyrrolidino-hexanophenone (MPHP); Bu phedrone; Methyl -N-
ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC);
Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC);
Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl -
alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-
alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC);
Methylbuphedrone (MBP); Benzedrone (4 -MBC); Dibutylone (DMBDB);
Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N -ethyl-N-
Methylcathinone; N -ethylbuphedrone, 1 -(1,3-benzodioxol-5-yl)2-
(ethylamino)pentan-1-one (N -Ethylpentylone); 4' -Methyl-alpha-
pyrrolidinopropiophenone (4 -MEPPP, MPPP or MαPPP); alpha -
Pyrrolidinobutiophenone (α -PBP); 1 -(1,3-benzodioxol-5-yl)-2-(tert-
butylamino)propan-1-one (Ter tylone); 1 -(1,3-benzodioxol-5-yl)-2-
(ethylamino)hexan-1-one (N-ethyl Hexylone); 1 -(1,3-benzodioxol-5-yl)-2-
(methylamino)pntan-1-one (Pentylone); N -ethylhexedrone (α
ethylaminohexanophenone); alpha -pyrrolidinohexanophenone (α-PHP); 4-methyl-
alpha-ethylaminopentiophenone (4 -MEAP); 4′ -methyl-alpha-
pyrrolidinohexiophenone (MPHP); alpha -pyrrolidinoheptaphenone (PV8); 4′ -
chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP); Alpha-PIHP (4-methyl-
1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one;
(39) 2,5-Dimethoxy-4-ethylamphetamine (DOET);
(40) Alpha-ethyltryptamine;
(41) 4-Bromo-2,5-dimethoxy phenethylamine;
(42) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
(43) 1-(3-trifluoromethylphenyl) piperazine (TFMPP);
(44) Alpha-methyltryptamine (AMT);
(45) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(46) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
(47) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is
not listed as a controlled substance in another schedule, is not an FDA-approved
drug, and contains any quantity of the following substances, their salts, isomers
(whether optical, positional, or geometric), homologues, modifications of the indole 25.232.16 7 35
SB35 ENROLLED
ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog
substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or
propionaldehyde structure, and salts of isomers, homologues, and modifications,
unless specifically excepted, whenever the existence of these salts, isomers,
homologues, modifications, and salts of isomers, homologues, and modifications is
possible within the specific chemical designation:
(a) Naphthoylindoles. Any compound containing a 2 -(1- naphthoyl)indole or 3-
(1-naphthoyl)indole structure with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
further substituted on the indole ring to any extent and whether or not
substituted on the naphthyl ring to any extent.
Some trade or other names: JWH -015; 1-pentyl-3-(1-naphthoyl)indole
(JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-
naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole
(JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-
morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398;
1-pentyl-3-(1-naphthoyl)indole (AM -678); 1 -(5-fluoropentyl)-3-(1-
naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009;
JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048;
JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079;
JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120;
JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182;
JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234;
JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262;
JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400;
JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220;
AM-1221; AM-1235; AM-2232, THJ-2201;
(b) Naphthylmethylindoles. Any compound containing a 1H -indol-2-yl-(1-
naphthyl)methane or 1H -indol-3-yl-(1-naphthyl)methane structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkyleth yl, 1 -(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1 -(N-methyl-2- 25.232.16 8 35
SB35 ENROLLED
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted
on the indole ring to any extent and whether or not substituted on the
naphthyl ring to any extent.
Some trade or other names: JWH -175; JWH-184; JWH-185; JWH-192;
JWH-194; JWH-195; JWH-196; JWH-197; JWH-199;
(c) Phenylacetylindoles. Any compound containing a 2-phenylacetylindole or 3-
phenylacetylindole structure with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
further substituted on the indole ring to any extent and whether or not
substituted on the phenyl ring to any extent.
Some trade or other names: 1 -cyc lohexylethyl-3-(2-
methoxyphenylacetyl)indole (SR -18); 1 -cyclohexylethyl-3-(2-
methoxyphenylacetyl)indole (RCS -8); 1 -pentyl-3-(2-
methoxyphenylacetyl)indole (JWH -250); 1 -pentyl-3-(2-
chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-
204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-
248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-
305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-
316; Cannabipiperidiethanone;
(d) Benzoylindoles. Any compound containing a 2 -(benzoyl)indole or 3-
(benzoyl)indole structure with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
further substituted on the indole ring to any extent and whether or not
substituted on the phenyl ring to any extent.
Some trade or other names: 1 -(5-fluoropentyl)-3-(2-iodobenzoyl)indole
(AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline
(WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630;
AM-661; AM-2233; AM-1241; 25.232.16 9 35
SB35 ENROLLED
(e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-
(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
cyanoalky, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
group, whether or not further substituted on the pyrrole ring to any extent
and whether or not substituted on the naphthyl ring to any extent.
Some trade or other names: JWH -307; JWH-030; JWH-031; JWH-145;
JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244;
JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346;
JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369;
JWH-370; JWH-371; JWH-373; JWH-392;
(f) Naphthylmethylindenes. Any compound containing a naphthylideneindene
structure with substitution at the 3-position of the indene ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted
on the indene ring to any extent and whether or not substituted on the
naphthyl ring to any extent.
Some trade or other names: JWH-171; JWH-176; JWH-220;
(g) Cyclohexylphenols. Any compound containing a 2 -(3-
hydroxycyclohexyl)phenol structure with substitution at the 5-position of
the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1 -(N-methyl-2-piperidinyl)methyl, or 2 -(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
group, whether or not substituted on the cyclohexyl ring to any extent.
Some trade or other names: 5 -(1,1-dimethylheptyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes
C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667;
(h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names:
HU-210; 25.232.16 10 35
SB35 ENROLLED
(i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3 -de]-1,4-
benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-
2;
(j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-
acetyl indole structure substituted at the acetyl by replacement of the
methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or
propionaldehyde substituent whether or not further substituted on the
tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde
substituent to any extent and whether or not further substituted at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
group whether or not further substituted on the indole ring to any extent.
Some trade and or names: (1 -Pentylindol-3-yl)-(2,2,3,3-
tetramethylcyclopropyl)methanone (UR -144); (1-(5-fluoropentyl)indol-3-
yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR -11); (1 -(2-
morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-
tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-
yl)methyl]-3-(adamant-1-oyl)indole (AM -1248); 1 -Pentyl-3-(1-
adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (1-
(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (FUB -144);
(k) Substituted Carboxamide Indole. Any compound containing a 2 -carboxamide
indole or 3-carboxamide indole structure substituted at the nitrogen of the
carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl,
phenyl, or propionaldehyde substituent, whether or not further substituted
on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or
propionaldehyde substituent to any extent and whether or not further
substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-
piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted
on the indole ring to any extent. 25.232.16 11 35
SB35 ENROLLED
Some trade and other names: JWH -018 adamantyl carboxamide; STS -135;
MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
pyrrolo[2,3-b]pyridine-3-carboxamide (5F -CUMYL-P7AICA) ; N -
(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F -
APINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-
3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(cyclohexylmethyl)indazole-3-carboxamide (AB -CHMINACA); 1 -(4-
cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-
CUMYL-BUTINACA); N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)indazole-3-carboxamide (ADB -CHMINACA or MAB -
CHMINACA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-
carbonyl]amino]-3,3-dimethylbutanoate (MDMB -FUBINACA); methyl 2-(1-
(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB -
CHMICA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-
carbonyl]amino]-3-methylbutanoate (AMB -FUBINACA); Methyl 2 -(1-(5-
fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
methyl 2 -(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-
dimethylbutaoate (5F-MDMB-PICA); methyl (S)-3,3-dimethyl-2-[(1-(pent-
4-enlindazole-3-carbonyl)amino]butanoate (MDMB -4en-PINACA); methyl
2-(1-(4-fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate
(4F-MDMB-BUTINACA); Ethyl 2 -(1-(5-fluoropentyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA); Methyl 2-(1-(5-
fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F -
MDMB-PICA); N -(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (FUB-APINACA); 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
1H-indazole-3-carboxamide (5F-CUMYL-PINACA);
(l) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-
carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl
group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl,
cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent
whether or not further substituted on the phenyl, benzyl, naphthyl,
adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde
substituent to any extent and whether or not further substituted at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- 25.232.16 12 35
SB35 ENROLLED
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group
whether or not further substituted on the indole ring to any extent.
Some trade and other names: Naphthalen-1-yl 1-(5-fluoropntyl)-1H-indole-
3-carboxylate (NM2201);
(48) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);
(49) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(50) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C -C);
(52) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C -I);
(53) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-2);
(54) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-4);
(55) 2-(2,5-Dimethoxyphenyl)ethanamine (2C -H);
(56) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(57) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(58) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a
controlled substance in another schedule or an approved FDA drug, structurally
derived from phenylethan-2-amine by substitution on the phenyl ring in any of the
following ways: by substitution with a fused methylenedioxy, fused furan, or fused
tetrahydrofuran ring system; by substitution with two alkoxy groups; by
substitution with one alkoxy and either one fused furan, tetrahydrofuran, or
tetrahydropyran ring system; by substitution with two fused ring systems from any
combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems;
whether or not the compound is further modified in any of the following ways:
(a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl,
trifluoromethyl, alkoxy, or alkylthio groups;
(b) By substitution on the 2-position by any alkyl groups; or
(c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl,
benzyl, methoxybenzyl, or hydroxybenzyl groups.
Some trade and other names: 2 -(2,5-dimethoxy-4-
(methylthio)phenyl)ethanamine (2C -T or 4 -methylthio-2,5-
dimethoxyphenethylamine); 1 -(2,5-dimethoxy-4-iodophenyl)-propan-2-amine
(DOI or 2, 5 -Dimethoxy-4-iodoamphetamine); 1 -(4-Bromo-2,5-
dimethoxyphenyl)-2-aminopropane (DOB or 2,5 -Dimethoxy-4-
bromoamphetamine); 1 -(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC 25.232.16 13 35
SB35 ENROLLED
or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-
[(2-methoxyphenyl)methyl]ethanamine (2C -B-NBOMe; 25B -NBOMe or 2,5 -
Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2 -4-iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethana mine (2C-I-NBOMe; 25I-
NBOMe or 2,5 -Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N -(2-
Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline -NBOMe or 3,4,5 -
trimethoxy-(2-methoxybenzyl)phenethylamine); 2 -(4-chloro-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-
NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2 -(7-
Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY);
2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-
FLY); 2 -(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
yl)ethanamine (2C -B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-
tetrahydrobenzo[1,2-b:4,5-bΝ]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe);
1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo -
benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-
2,5-dimethoxyphenethylamine (2C -I-NBOH or 25I -NBOH); 5 -(2-
Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-
Aminopropyl)-2,3-dihydrobenzofuran (5 -APDB); 6 -(2-Aminopropyl)-2,3,-
dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA);
(59) Substituted tryptamines. Any compound, unless specifically exempt, listed as a
controlled substance in another schedule or an approved FDA drug, structurally
derived from 2-(1H-indol-3-yl)ethanamine by mono - or di-substitution of the
amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen
atom in a cyclic structure whether or not the compound is further substituted at
the alpha-position with an alkyl group or whether or not further substituted on the
indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.
Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-
acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-
methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-
HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
(60) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13);
(61) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48);
(62) 1-(4-Fluorophenyl)piperazine (pFPP);
(63) 1-(3-Chlorophenyl)piperazine (mCPP); 25.232.16 14 35
SB35 ENROLLED
(64) 1-(4-Methoxyphenyl)piperazine (pMeOPP);
(65) 1,4-Dibenzylpiperazine (DBP);
(66) Isopentedrone;
(67) Fluoromethamphetamine;
(68) Fluoroamphetamine;
(69) Fluorococaine;
(70) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
(71) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22);
(72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-
PINACA);
(73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide (5 Fluoro-AB-PINACA);
(74) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (AB-FUBINACA);
(75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide
(ADB-PINACA (ADBICA));
(76) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA));
(77) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (ADB-FUBINACA);
(78) N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-
3-carboxamide (5-Fluoro-3,5-AB-PFUPPYCA); and
(79) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine).
Section 3. Whereas, this Act is necessary for the immediate preservation of the public peace,
health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force
and effect from and after its passage and approval. 25.232.16 15 35
SB35 ENROLLED
An Act to modify substances listed on the controlled substances schedule and to declare an
emergency.
I certify that the attached Act originated in
the:
Senate as Bill No. 35
Secretary of the Senate
President of the Senate
Attest:
Secretary of the Senate
Speaker of the House
Attest:
Chief Clerk
Senate Bill No. 35
File No. ____
Chapter No. ______
Received at this Executive Office
this _____ day of _____________,
2025 at ____________M.
By
for the Governor
The attached Act is hereby
approved this ________ day of
______________, A.D., 2025
Governor
STATE OF SOUTH DAKOTA ,
ss.
Office of the Secretary of State
Filed ____________, 2025
at _________ o'clock __M.
Secretary of State
By
Asst. Secretary of State